O	0	11	Association
O	12	14	of
B-intervention	15	25	Menopausal
I-intervention	26	33	Hormone
I-intervention	34	41	Therapy
O	42	46	With
O	47	53	Breast
O	54	60	Cancer
O	61	70	Incidence
O	71	74	and
O	75	84	Mortality
O	85	91	During
O	92	96	Long
O	96	97	-
O	97	101	term
O	102	108	Follow
O	108	109	-
O	109	111	up
O	112	114	of
O	115	118	the
O	119	124	Women
O	124	125	'
O	125	126	s
O	127	133	Health
O	134	144	Initiative
O	145	155	Randomized
O	156	164	Clinical
O	165	171	Trials
O	171	172	.

O	173	176	The
O	177	186	influence
O	187	189	of
O	190	200	menopausal
O	201	208	hormone
O	209	216	therapy
O	217	219	on
O	220	226	breast
O	227	233	cancer
O	234	241	remains
O	242	251	unsettled
O	252	256	with
O	257	267	discordant
O	268	276	findings
O	277	281	from
O	282	295	observational
O	296	303	studies
O	304	307	and
O	308	318	randomized
O	319	327	clinical
O	328	334	trials
O	334	335	.

O	336	338	To
O	339	345	assess
O	346	349	the
O	350	361	association
O	362	364	of
O	365	370	prior
O	371	381	randomized
O	382	385	use
O	386	388	of
O	389	397	estrogen
O	398	402	plus
O	403	412	progestin
O	413	415	or
O	416	421	prior
O	422	432	randomized
O	433	436	use
O	437	439	of
O	440	448	estrogen
O	449	454	alone
O	455	459	with
O	460	466	breast
O	467	473	cancer
O	474	483	incidence
O	484	487	and
O	488	497	mortality
O	498	500	in
O	501	504	the
O	505	510	Women
O	510	511	'
O	511	512	s
O	513	519	Health
O	520	530	Initiative
O	531	539	clinical
O	540	546	trials
O	546	547	.

O	548	552	Long
O	552	553	-
O	553	557	term
O	558	564	follow
O	564	565	-
O	565	567	up
O	568	570	of
O	571	572	2
O	573	580	placebo
O	580	581	-
O	581	591	controlled
O	592	602	randomized
O	603	611	clinical
O	612	618	trials
O	619	623	that
O	624	632	involved
B-total-participants	633	635	27
I-total-participants	636	639	347
B-eligibility	640	654	postmenopausal
I-eligibility	655	660	women
O	661	665	aged
B-age	666	668	50
I-age	669	676	through
I-age	677	679	79
I-age	680	685	years
B-eligibility	686	690	with
I-eligibility	691	693	no
I-eligibility	694	699	prior
I-eligibility	700	706	breast
I-eligibility	707	713	cancer
I-eligibility	714	717	and
I-eligibility	718	726	negative
I-eligibility	727	735	baseline
I-eligibility	736	745	screening
I-eligibility	746	755	mammogram
O	755	756	.

O	757	762	Women
O	763	767	were
O	768	776	enrolled
O	777	779	at
O	780	782	40
B-location	783	785	US
O	786	793	centers
O	794	798	from
O	799	803	1993
O	804	806	to
O	807	811	1998
O	812	816	with
O	817	823	follow
O	823	824	-
O	824	826	up
O	827	834	through
O	835	843	December
O	844	846	31
O	846	847	,
O	848	852	2017
O	852	853	.

O	854	856	In
O	857	860	the
O	861	866	trial
O	867	876	involving
B-total-participants	877	879	16
I-total-participants	880	883	608
O	884	889	women
O	890	894	with
O	895	896	a
O	897	903	uterus
O	903	904	,
B-intervention-participants	905	909	8506
O	910	914	were
O	915	925	randomized
O	926	928	to
O	929	936	receive
O	937	938	0
O	938	939	.
O	939	942	625
O	943	945	mg
O	945	946	/
O	946	947	d
O	948	950	of
B-intervention	951	961	conjugated
I-intervention	962	968	equine
I-intervention	969	977	estrogen
I-intervention	978	979	(
I-intervention	979	982	CEE
I-intervention	982	983	)
O	984	988	plus
O	989	990	2
O	990	991	.
O	991	992	5
O	993	995	mg
O	995	996	/
O	996	997	d
O	998	1000	of
O	1001	1020	medroxyprogesterone
O	1021	1028	acetate
O	1029	1030	(
O	1030	1033	MPA
O	1033	1034	)
O	1035	1038	and
B-control-participants	1039	1043	8102
O	1043	1044	,
B-control	1045	1052	placebo
O	1052	1053	.

O	1054	1056	In
O	1057	1060	the
O	1061	1066	trial
O	1067	1076	involving
B-total-participants	1077	1079	10
I-total-participants	1080	1083	739
O	1084	1089	women
O	1090	1094	with
O	1095	1100	prior
O	1101	1113	hysterectomy
O	1113	1114	,
B-intervention-participants	1115	1119	5310
O	1120	1124	were
O	1125	1135	randomized
O	1136	1138	to
O	1139	1146	receive
O	1147	1148	0
O	1148	1149	.
O	1149	1152	625
O	1153	1155	mg
O	1155	1156	/
O	1156	1157	d
O	1158	1160	of
O	1161	1164	CEE
O	1165	1170	alone
O	1171	1174	and
B-control-participants	1175	1179	5429
O	1179	1180	,
O	1181	1188	placebo
O	1188	1189	.

O	1190	1193	The
O	1194	1197	CEE
O	1197	1198	-
O	1198	1202	plus
O	1202	1203	-
O	1203	1206	MPA
O	1207	1212	trial
O	1213	1216	was
O	1217	1224	stopped
O	1225	1227	in
O	1228	1232	2002
O	1233	1238	after
O	1239	1240	5
O	1240	1241	.
O	1241	1242	6
O	1243	1248	years
O	1248	1249	'
O	1250	1256	median
O	1257	1269	intervention
O	1270	1278	duration
O	1278	1279	,
O	1280	1283	and
O	1284	1287	the
O	1288	1291	CEE
O	1291	1292	-
O	1292	1296	only
O	1297	1302	trial
O	1303	1306	was
O	1307	1314	stopped
O	1315	1317	in
O	1318	1322	2004
O	1323	1328	after
O	1329	1330	7
O	1330	1331	.
O	1331	1332	2
O	1333	1338	years
O	1338	1339	'
O	1340	1346	median
O	1347	1359	intervention
O	1360	1368	duration
O	1368	1369	.

O	1370	1373	The
O	1374	1381	primary
O	1382	1389	outcome
O	1390	1393	was
B-outcome-Measure	1394	1400	breast
I-outcome-Measure	1401	1407	cancer
I-outcome-Measure	1408	1417	incidence
O	1418	1419	(
O	1419	1427	protocol
O	1428	1440	prespecified
O	1441	1448	primary
O	1449	1459	monitoring
O	1460	1467	outcome
O	1468	1471	for
O	1472	1476	harm
O	1476	1477	)
O	1478	1481	and
O	1482	1491	secondary
O	1492	1500	outcomes
O	1501	1505	were
B-outcome-Measure	1506	1512	deaths
I-outcome-Measure	1513	1517	from
I-outcome-Measure	1518	1524	breast
I-outcome-Measure	1525	1531	cancer
I-outcome-Measure	1532	1535	and
I-outcome-Measure	1536	1542	deaths
I-outcome-Measure	1543	1548	after
I-outcome-Measure	1549	1555	breast
I-outcome-Measure	1556	1562	cancer
O	1562	1563	.

O	1564	1569	Among
B-total-participants	1570	1572	27
I-total-participants	1573	1576	347
O	1577	1591	postmenopausal
O	1592	1597	women
O	1598	1601	who
O	1602	1606	were
O	1607	1617	randomized
O	1618	1620	in
O	1621	1625	both
O	1626	1632	trials
O	1633	1634	(
O	1634	1642	baseline
O	1643	1647	mean
O	1648	1649	[
O	1649	1651	SD
O	1651	1652	]
O	1653	1656	age
O	1656	1657	,
B-age	1658	1660	63
I-age	1660	1661	.
I-age	1661	1662	4
I-age	1663	1668	years
I-age	1669	1670	[
I-age	1670	1671	7
I-age	1671	1672	.
I-age	1672	1673	2
I-age	1674	1679	years
I-age	1679	1680	]
O	1680	1681	)
O	1681	1682	,
O	1683	1688	after
O	1689	1693	more
O	1694	1698	than
O	1699	1701	20
O	1702	1707	years
O	1708	1710	of
O	1711	1717	median
O	1718	1728	cumulative
O	1729	1735	follow
O	1735	1736	-
O	1736	1738	up
O	1738	1739	,
O	1740	1749	mortality
O	1750	1761	information
O	1762	1765	was
O	1766	1775	available
O	1776	1779	for
O	1780	1784	more
O	1785	1789	than
O	1790	1792	98
O	1792	1793	%
O	1793	1794	.

O	1795	1798	CEE
O	1799	1804	alone
O	1805	1813	compared
O	1814	1818	with
O	1819	1826	placebo
O	1827	1832	among
B-intervention-participants	1833	1835	10
I-intervention-participants	1836	1839	739
O	1840	1845	women
O	1846	1850	with
O	1851	1852	a
O	1853	1858	prior
O	1859	1871	hysterectomy
O	1872	1875	was
O	1876	1886	associated
O	1887	1891	with
O	1892	1905	statistically
O	1906	1919	significantly
O	1920	1925	lower
B-outcome	1926	1932	breast
I-outcome	1933	1939	cancer
I-outcome	1940	1949	incidence
O	1950	1954	with
B-iv-bin-abs	1955	1958	238
O	1959	1964	cases
O	1965	1966	(
O	1966	1976	annualized
O	1977	1981	rate
O	1981	1982	,
B-iv-bin-percent	1983	1984	0
I-iv-bin-percent	1984	1985	.
I-iv-bin-percent	1985	1987	30
I-iv-bin-percent	1987	1988	%
O	1988	1989	)
O	1990	1992	vs
B-cv-bin-abs	1993	1996	296
O	1997	2002	cases
O	2003	2004	(
O	2004	2014	annualized
O	2015	2019	rate
O	2019	2020	,
B-cv-bin-percent	2021	2022	0
I-cv-bin-percent	2022	2023	.
I-cv-bin-percent	2023	2025	37
I-cv-bin-percent	2025	2026	%
O	2026	2027	;
O	2028	2034	hazard
O	2035	2040	ratio
O	2041	2042	[
O	2042	2044	HR
O	2044	2045	]
O	2045	2046	,
O	2047	2048	0
O	2048	2049	.
O	2049	2051	78
O	2051	2052	;
O	2053	2055	95
O	2055	2056	%
O	2057	2059	CI
O	2059	2060	,
O	2061	2062	0
O	2062	2063	.
O	2063	2065	65
O	2065	2066	-
O	2066	2067	0
O	2067	2068	.
O	2068	2070	93
O	2070	2071	;
O	2072	2073	P
O	2074	2075	=
O	2076	2077	.
O	2077	2080	005
O	2080	2081	)
O	2082	2085	and
O	2086	2089	was
O	2090	2100	associated
O	2101	2105	with
O	2106	2119	statistically
O	2120	2133	significantly
O	2134	2139	lower
B-outcome	2140	2146	breast
I-outcome	2147	2153	cancer
I-outcome	2154	2163	mortality
O	2164	2168	with
B-iv-bin-abs	2169	2171	30
O	2172	2178	deaths
O	2179	2180	(
O	2180	2190	annualized
O	2191	2200	mortality
O	2201	2205	rate
O	2205	2206	,
B-iv-bin-percent	2207	2208	0
I-iv-bin-percent	2208	2209	.
I-iv-bin-percent	2209	2212	031
I-iv-bin-percent	2212	2213	%
O	2213	2214	)
O	2215	2217	vs
B-cv-bin-abs	2218	2220	46
O	2221	2227	deaths
O	2228	2229	(
O	2229	2239	annualized
O	2240	2249	mortality
O	2250	2254	rate
O	2254	2255	,
B-cv-bin-percent	2256	2257	0
I-cv-bin-percent	2257	2258	.
I-cv-bin-percent	2258	2261	046
I-cv-bin-percent	2261	2262	%
O	2262	2263	;
O	2264	2266	HR
O	2266	2267	,
O	2268	2269	0
O	2269	2270	.
O	2270	2272	60
O	2272	2273	;
O	2274	2276	95
O	2276	2277	%
O	2278	2280	CI
O	2280	2281	,
O	2282	2283	0
O	2283	2284	.
O	2284	2286	37
O	2286	2287	-
O	2287	2288	0
O	2288	2289	.
O	2289	2291	97
O	2291	2292	;
O	2293	2294	P
O	2295	2296	=
O	2297	2298	.
O	2298	2300	04
O	2300	2301	)
O	2301	2302	.

O	2303	2305	In
O	2306	2314	contrast
O	2314	2315	,
O	2316	2319	CEE
O	2320	2324	plus
O	2325	2328	MPA
O	2329	2337	compared
O	2338	2342	with
O	2343	2350	placebo
O	2351	2356	among
B-control-participants	2357	2359	16
I-control-participants	2360	2363	608
O	2364	2369	women
O	2370	2374	with
O	2375	2376	a
O	2377	2383	uterus
O	2384	2387	was
O	2388	2398	associated
O	2399	2403	with
O	2404	2417	statistically
O	2418	2431	significantly
O	2432	2438	higher
B-outcome	2439	2445	breast
I-outcome	2446	2452	cancer
I-outcome	2453	2462	incidence
O	2463	2467	with
B-iv-bin-abs	2468	2471	584
O	2472	2477	cases
O	2478	2479	(
O	2479	2489	annualized
O	2490	2494	rate
O	2494	2495	,
B-iv-bin-percent	2496	2497	0
I-iv-bin-percent	2497	2498	.
I-iv-bin-percent	2498	2500	45
I-iv-bin-percent	2500	2501	%
O	2501	2502	)
O	2503	2505	vs
B-cv-bin-abs	2506	2509	447
O	2510	2515	cases
O	2516	2517	(
O	2517	2527	annualized
O	2528	2532	rate
O	2532	2533	,
B-cv-bin-percent	2534	2535	0
I-cv-bin-percent	2535	2536	.
I-cv-bin-percent	2536	2538	36
I-cv-bin-percent	2538	2539	%
O	2539	2540	;
O	2541	2543	HR
O	2543	2544	,
O	2545	2546	1
O	2546	2547	.
O	2547	2549	28
O	2549	2550	;
O	2551	2553	95
O	2553	2554	%
O	2555	2557	CI
O	2557	2558	,
O	2559	2560	1
O	2560	2561	.
O	2561	2563	13
O	2563	2564	-
O	2564	2565	1
O	2565	2566	.
O	2566	2568	45
O	2568	2569	;
O	2570	2571	P
O	2572	2573	<
O	2574	2575	.
O	2575	2578	001
O	2578	2579	)
O	2580	2583	and
O	2584	2586	no
O	2587	2598	significant
O	2599	2609	difference
O	2610	2612	in
B-outcome	2613	2619	breast
I-outcome	2620	2626	cancer
I-outcome	2627	2636	mortality
O	2637	2641	with
B-iv-bin-abs	2642	2644	71
O	2645	2651	deaths
O	2652	2653	(
O	2653	2663	annualized
O	2664	2673	mortality
O	2674	2678	rate
O	2678	2679	,
B-iv-bin-percent	2680	2681	0
I-iv-bin-percent	2681	2682	.
I-iv-bin-percent	2682	2685	045
I-iv-bin-percent	2685	2686	%
O	2686	2687	)
O	2688	2690	vs
B-cv-bin-abs	2691	2693	53
O	2694	2700	deaths
O	2701	2702	(
O	2702	2712	annualized
O	2713	2722	mortality
O	2723	2727	rate
O	2727	2728	,
B-cv-bin-percent	2729	2730	0
I-cv-bin-percent	2730	2731	.
I-cv-bin-percent	2731	2734	035
I-cv-bin-percent	2734	2735	%
O	2735	2736	;
O	2737	2739	HR
O	2739	2740	,
O	2741	2742	1
O	2742	2743	.
O	2743	2745	35
O	2745	2746	;
O	2747	2749	95
O	2749	2750	%
O	2751	2753	CI
O	2753	2754	,
O	2755	2756	0
O	2756	2757	.
O	2757	2759	94
O	2759	2760	-
O	2760	2761	1
O	2761	2762	.
O	2762	2764	95
O	2764	2765	;
O	2766	2767	P
O	2767	2768	=
O	2769	2770	.
O	2770	2772	11
O	2772	2773	)
O	2773	2774	.

O	2775	2777	In
O	2778	2782	this
O	2783	2787	long
O	2787	2788	-
O	2788	2792	term
O	2793	2799	follow
O	2799	2800	-
O	2800	2802	up
O	2803	2808	study
O	2809	2811	of
O	2812	2813	2
O	2814	2824	randomized
O	2825	2831	trials
O	2831	2832	,
O	2833	2838	prior
O	2839	2849	randomized
O	2850	2853	use
O	2854	2856	of
O	2857	2860	CEE
O	2861	2866	alone
O	2866	2867	,
O	2868	2876	compared
O	2877	2881	with
O	2882	2889	placebo
O	2889	2890	,
O	2891	2896	among
O	2897	2902	women
O	2903	2906	who
O	2907	2910	had
O	2911	2912	a
O	2913	2921	previous
O	2922	2934	hysterectomy
O	2934	2935	,
O	2936	2939	was
O	2940	2953	significantly
O	2954	2964	associated
O	2965	2969	with
O	2970	2975	lower
O	2976	2982	breast
O	2983	2989	cancer
O	2990	2999	incidence
O	3000	3003	and
O	3004	3009	lower
O	3010	3016	breast
O	3017	3023	cancer
O	3024	3033	mortality
O	3033	3034	,
O	3035	3042	whereas
O	3043	3048	prior
O	3049	3059	randomized
O	3060	3063	use
O	3064	3066	of
O	3067	3070	CEE
O	3071	3075	plus
O	3076	3079	MPA
O	3079	3080	,
O	3081	3089	compared
O	3090	3094	with
O	3095	3102	placebo
O	3102	3103	,
O	3104	3109	among
O	3110	3115	women
O	3116	3119	who
O	3120	3123	had
O	3124	3126	an
O	3127	3133	intact
O	3134	3140	uterus
O	3140	3141	,
O	3142	3145	was
O	3146	3159	significantly
O	3160	3170	associated
O	3171	3175	with
O	3176	3177	a
O	3178	3184	higher
O	3185	3191	breast
O	3192	3198	cancer
O	3199	3208	incidence
O	3209	3212	but
O	3213	3215	no
O	3216	3227	significant
O	3228	3238	difference
O	3239	3241	in
O	3242	3248	breast
O	3249	3255	cancer
O	3256	3265	mortality
O	3265	3266	.
